Evidence map›Paper›PMID 31199565›Full record

ArticleArthritis care & research2020

American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans.

R Hal Scofield, Rohan Sharma, Nathan Pezant, Jennifer A Kelly, Lida Radfar, David M Lewis, C Erick Kaufman, Sarah Cioli, Judy Harris, Kiely Grundahl and 10 more

Open access · greenAbstract read
In one paragraph

Article in Arthritis care & research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Molecular Decolonization: An Indigenous Microcosm Perspective of Planetary Health.International journal of environmental research and public health · 2020
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

R Hal ScofieldOklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, and Department of Veterans Affairs Medical Center, Oklahoma City.ORCID 0000-0003-1015-5850
Rohan SharmaUniversity of Arkansas for Medical Sciences, Little Rock.
Nathan PezantOklahoma Medical Research Foundation, Oklahoma City.
Jennifer A KellyOklahoma Medical Research Foundation, Oklahoma City.
Lida RadfarUniversity of Oklahoma College of Dentistry, Oklahoma City.
David M LewisUniversity of Oklahoma College of Dentistry, Oklahoma City.
C Erick KaufmanUniversity of Oklahoma Health Sciences Center, Oklahoma City.
Sarah CioliOklahoma Medical Research Foundation, Oklahoma City.
Judy HarrisOklahoma Medical Research Foundation, Oklahoma City.
Kiely GrundahlOklahoma Medical Research Foundation, Oklahoma City.
Nelson L RhodusUniversity of Minnesota School of Dentistry, Minneapolis.
Daniel J WallaceCedars-Sinai Medical Center, Los Angeles, California, USA.
Michael H WeismanCedars-Sinai Medical Center, Los Angeles, California, USA.
Swamy VenuturupalliCedars-Sinai Medical Center, Los Angeles, California, USA.
Michael T BrennanCarolinas Medical Center, Charlotte, North Carolina.
Kristi A KoelschOklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.
Christopher J LessardOklahoma Medical Research Foundation, Oklahoma City.ORCID 0000-0003-2440-3843
Courtney G MontgomeryOklahoma Medical Research Foundation, Oklahoma City.ORCID 0000-0002-9606-3772
Kathy L SivilsOklahoma Medical Research Foundation, Oklahoma City.
Astrid RasmussenOklahoma Medical Research Foundation, Oklahoma City, Oklahoma, and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0001-7744-2948
Oklahoma Medical Research Foundation · USCedars-Sinai Medical Center · USOklahoma City University · USCarolinas Medical Center · USUniversity of Arkansas for Medical Sciences · USUniversity of Minnesota · USUniversity of Oklahoma Health Sciences Center · USUniversity of Oklahoma Medical Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
VALIDATING NOVEL GENES IMPLICATED IN LEUKOCYTE CHEMOTAXISP20RR020143 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SAWALHA, AMR H · 2004 to 2011
$21.0M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
Pathogenic B Cells in Sjogren's SyndromeP50AR060804 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI SCOFIELD, ROBERT HAL · 2011 to 2015
$7.9M
HLA GENE COMPLEMENTATION IN PRIMARY SJOGREN'S AND LUPUSR01AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KOTTYAN, LEAH CLAIRE, WEIRAUCH, MATTHEW TYSON · 1987 to 2025
$7.8M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Genetic Linkage in LupusR37AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI HARLEY, JOHN BARKER · 2005 to 2014
$4.2M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
Functional Evaluation of Established Sjogren's Syndrome Immune Response LociR01AR065953 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI LESSARD, CHRISTOPHER J · 2015 to 2018
$2.1M
Genetic Association in Sjogren's SyndromeR01DE015223 · NIDCR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI HARLEY, JOHN BARKER · 2004 to 2008
$1.9M
BLRD VA I01 BX001451NCRR NIH HHS P20 RR020143NIAID NIH HHS R01 AI024717NIAID NIH HHS R37 AI024717NIAID NIH HHS R56 AI118787NIAID NIH HHS U19 AI082714NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P30 AR073750NIAMS NIH HHS P50 AR060804NIAMS NIH HHS R01 AR050782NIAMS NIH HHS R01 AR065953NIDCR NIH HHS R01 DE015223NIDCR NIH HHS R01 DE018209NIDCR NIH HHS R21 DE021854NIGMS NIH HHS P30 GM103510NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

objectiveTo describe the clinical and serologic manifestations of Sjögren's syndrome (SS) in ethnic groups of the US.

methodsThis was a cross-sectional study of 648 patients with primary SS: 20 African American (AA), 164 American Indian (AI), 426 European American (EA), and 38 patients of other races evaluated in a multidisciplinary Sjögren's International Collaborative Clinical Alliance research clinic.

resultsAA subjects comprised 3.1% of the SS cohort, much lower than the percentage of AA in the state of Oklahoma (P = 3.01 × E - 05), the US (P = 2.24E - 13), or a systemic lupus erythematosus (SLE) cohort at the same institution (P = 4.26 × 10E - 27). In contrast, the percentage of AI in the SS cohort (25.3%) was much higher than expected (P = 3.17E - 09 versus SLE cohort, P = 6.36 - 26 versus Oklahoma, and P = 8.14E - 96 versus US population). The SS classification criteria were similar between AA and EA, but subjects of AI ancestry had lower rates of abnormal tear and salivary flow, as well as anti-Ro/SSA and anti-La/SSB antibodies. Paradoxically, AI had higher levels of disease activity (mean ± SD European League Against Rheumatism Sjögren's Syndrome Disease Activity Index score 3.77 ± 4.78) in comparison to EA (2.90 ± 4.12; P = 0.011) and more extraglandular manifestations affecting mainly the articular and glandular domains. Meanwhile, AA patients were characterized by higher rates of hypergammaglobulinemia (odds ratio [OR] 1.39 [95% confidence interval (95% CI) 1.39-8.65]; P = 0.01), elevated erythrocyte sedimentation rate (ESR) (OR 3.95 [95% CI 1.46-9.95]; P = 0.009), and parotid enlargement (OR 4.40 [95% CI 1.49-13.07]; P = 0.02).

conclusionAI are affected at high rates with SS but present with few classical features, potentially preventing timely diagnosis. In contrast to SLE, SS is infrequent and not more severe among AA, but the triad of hypergammaglobulinemia, increased ESR, and parotid enlargement warrants extra vigilance for lymphomagenesis.

Indexed as

AdultBlack or African AmericanCross-Sectional StudiesFemaleHumansIndians, North AmericanMaleMiddle AgedOklahomaRisk FactorsSjogren's SyndromeWhite People

Identifiers

PMID31199565
PMCPMC6911033
OpenAlexW2949917660

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.